ABSTRACT

Objective:

The aim of this study was to determine the frequency of toxoplasmosis in pregnant women who were admitted to our hospital in their first trimester and to contribute to screening and management strategies by evaluating clinical outcomes.

Methods:

In this retrospective study, women in their first trimester of pregnancy who were aged between 15-49 years, admitted to the Mersin University Medical Faculty Gynecology and Obstetrics outpatient clinic between 2012-2017, and screened for Toxoplasma gondii immunoglobulin M (IgM) antibodies were included. The data was obtained from the hospital’s digital records. First, the high-risk patients were identified who had anti-T. gondii IgM seropositivity and subsequently underwent anti-T. gondii immunoglobulin G (IgG) and anti-T. gondii IgG avidity tests. Next, the invasive procedures and medical treatments performed for diagnosis and treatment, as well as the clinical course and results for each patient were evaluated. Cases were then analyzed according to the admittance year and patient’s age.

Results:

Anti-T. gondii IgM positivity was found in 266 (7.66%) of 3474 pregnant women meeting the study’s criteria. The frequency of the Toxoplasma IgM seropositivity was the highest in the 15-25 age group and this frequency decreased gradually as the age of the patients increased. Congenital toxoplasmosis was detected in 1 of 61 patients who had a positive polymerase chain reaction for T. gondii performed in the amniotic fluid.

Conclusion:

In our province, the prevalence of anti-T. gondii IgM was found to be 7.66% in pregnant women who were admitted to a tertiary health institution in their first trimester of pregnancy. This rate is much higher than the average in Turkey; therefore, we suggest that routine screening of pregnant women for T. gondii may be recommended in this region.

Keywords: Toxoplasma gondii, polymerase chain reaction, pregnancy, fetal anomaly

References

Uludağ S, Madazlı R, Şen C, Ocak V. Gebelik ve Toksoplazmozis’de Klinik Yönetim. Perinatoloji Dergisi 1993;1:165-9.

Welton NJ, Ades AE. A model of toxoplasmosis incidence in the UK: Evidence synthesis and consistency of evidence. JRSS-C Applied Statistics 2005;54:385-404.

Remington JS, McLeod R, Thulliez P, Desmonts G. Toxoplasmosis. In: Infectious Disease of the Fetus adn Newborn Infant, 6th ed, Remington JS, Klein J, Wilson CB, Baker CJ Editors. Elsevier Saunders: Philadelphia; 2006.p.947.

SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group, Thiébaut R, Leproust S, Chêne G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients’ data. Lancet 2007;369:115-22.

Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 1999;353:1829-33.

Gilbert RE, Peckham CS. Congenital toxoplasmosis in the United Kingdom: to screen or not to screen? J Med Screen 2002;9:135-41.

Gilbert R, Gras L, European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 2003;110:112-20.

Paquet C, Yudin MH. No. 285-Toxoplasmosis in Pregnancy: Prevention, Screening, and Treatment. J Obstet Gynaecol Can 2018;40:687-93.

American College of Obstetricians and Gynecologists. Practice bulletin no. 151: Cytomegalovirus, Parvovirus B19, Varicella zoster, and toxoplasmosis in pregnancy. Obstet Gynecol 2015;125:1510-25.

Müngen E. Gebelikte Toksoplazmozis Taraması. Perinatoloji Dergisi 2010;18:69-71.

Gilbert R, Petersen E, Toxoplasmosis and pregnancy. Up to Date 2019. Available: URL: https://www.uptodate.com/contents/toxoplasmosis-and pregnancy?.

Bakacak M, Bostancı MS, Köstü B, Ercan Ö, Serin S, Avcı F, et al. Gebelerde Toxoplasma gondii, Rubella ve Sitomegalovirüs seroprevalansı. Dicle Tıp Dergisi 2014;41:326-31.

Mandelbrot L, Kieffer F, Sitta R, Laurichesse-Delmas H, Winer N, Mesnard L, et al. Prenatal therapy with pyrimethamine+sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol 2018;219:386.e1-386.e9.

Malatyalı E, Yıldız M, Tileklioğlu E, Ertabaklar H, Ertuğ S. Adnan Menderes Üniversitesi Tıp Fakültesi Parazitoloji Laboratuvarı 2007-2017 Yılları Arası Toxoplasma gondii Seroloji Sonuçlarının Retrospektif Olarak Değerlendirilmesi. Turkiye Parazitol Derg 2019;43:1-4.

Çiçek AÇ, Duygu F, İnakçı İH, Boyar N, Boyar İH. Şanlıurfa ilinde doğurganlık çağındaki kadınlarda ELISA ile Toxoplasma gondii antikorlarının araştırılması: Üç yıllık değerlendirme Journal of Clinical and Experimental Investigations 2012;3:61-5.

Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis 2002;185:73-82.

Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004;363:1965-76.

de Oliveira Azevedo CT, do Brasil PE, Guida L, Lopes Moreira ME. Performance of Polymerase Chain Reaction Analysis of the Amniotic Fluid of Pregnant Women for Diagnosis of Congenital Toxoplasmosis: A Systematic Review and Meta-Analysis. PLoS One 2016;7:11.e0149938.

Cortina-Borja M, Tan HK, Wallon M, Paul M, Prusa A, Buffolano W, et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. PLoS Med 2010;12:7-10.

Montoya JG. Systematic screening and treatment of toxoplasmosis during pregnancy: is the glass half full or half empty? Am J Obstet Gynecol 2018;219:315-9.

Retrospective Evaluation of the Seropositivity Rate of Toxoplasmosis and Clinical Results in Pregnant Women That were Admitted to a Tertiary Health Institution Between 2012 and 2017 in Turkey

ABSTRACT

References